Primary and acquired resistance to the breast cancer drug trastuzumab (Herceptin) is a significant clinical problem. Here, we report enhanced activation of downstream signaling pathways emanating from the growth factor receptors erbB2, erbB3, and insulin−like growth factor−I receptor (IGF−IR) in trastuzumab−resistant breast cancer cells. »
02/01/10

The insulin−like growth factor (IGF) signaling system is involved in breast cancer initiation and progression. The prognostic relevance of tumor expression patterns of IGFI−related proteins remains poorly understood. This study associates the expression of selected IGF proteins with breast tumor and patient characteristics. »
01/26/10

Development of breast cancer involves genetic factors as well as lifetime exposure to estrogen. The precise molecular mechanisms whereby estrogens influence breast tumor formation are poorly understood. While estrogen receptor alpha (ERalpha) is certainly involved, non−receptor mediated effects of estradiol (E(2)) may also play an important role in facilitating breast tumor development. »
01/26/10

Cisplatin is a chemotherapeutic agent not used routinely for breast cancer treatment. As a DNA cross−linking agent, cisplatin may be effective treatment for hereditary BRCA1−mutated breast cancers. Because sporadic triple−negative breast cancer (TNBC) and BRCA1−associated breast cancer share features suggesting common pathogenesis, we conducted a neoadjuvant trial of cisplatin in TNBC and explored specific biomarkers to identify predictors of response. »
01/25/10

Women with breast cancer (BC) treated with aromatase inhibitors (AIs) may experience joint symptoms that can lead to discontinuation of effective therapy. We examined whether acupuncture improves AI−induced arthralgias in women with early−stage BC. »
01/25/10

Both migraine and breast cancer are hormonally mediated. Two recent reports indicate that women with a migraine history may have a lower risk of postmenopausal breast cancer than those who never suffered migraines. This finding requires confirmation; in particular, an assessment of the influence of use of nonsteroidal anti−inflammatory drugs (NSAID) is needed, because many studies indicate that NSAID use also may confer a reduction in breast cancer risk. »
01/25/10

Cancer and its treatments have a lingering and often negative impact on survivors' physical well−being. The physical sequelae impinge on daily functioning and overall HRQOL, and perhaps influence lifestyle changes post−cancer. This study aims to examine: (1) physical well−being items that are associated with low overall health−related quality of life; and (2) the relationship between physical well−being outcomes and healthy lifestyle changes by cancer type. »
01/25/10

The carcinogenesis of cervical carcinoma implies an intricate interplay of neoplastic, human papillomavirus infected epithelial cells and stromal tissue, in which different factors have distinct but interacting influence. Persistent infection with an oncogenic human papillomavirus type may lead to epithelial dysplasia with progressive severity. »
01/22/10

Producing effective therapeutic vaccines has proved much more difficult and challenging than developing cancer preventive vaccines. Despite huge research in the area of cancer immunology, FDA/EMEA have not approved any type of cancer treatment vaccine so far. More than 99% of cervical cancers have detectable amounts of human papillomavirus (HPV) DNA. »
09/14/09

Cervical cancer is one of the most common gynecological malignancies in Korea, although the incidence has been declining in recent years. This study explored whether antioxidant vitamin intakes influenced the risk of cervical cancer. The association between antioxidant vitamin intakes and cervical cancer risk was calculated for 144 cervical cancer cases and 288 age−matched, hospital−based controls using unconditional logistic regression models. »
01/22/10